Latest News
Conference Coverage
IL inhibitor options move psoriasis treatment forward
Long-term data continue to support the safety and effectiveness of IL-17 and IL-23 inhibitor drugs.
News
Adalimumab safety update finds no new signals
The new integrated analysis includes safety data from five clinical trials that were not included in the analysis from 2009.
News
No evidence of subclinical axial involvement seen in skin psoriasis
Patients with longstanding psoriasis without peripheral or axial inflammation are unlikely to have subclinical involvement of the sacroiliac joint...
Latest News
Novel oral agent shows unprecedented efficacy in psoriasis
PARIS – Selective tyrosine kinase 2 inhibitor reached a 75% PASI 75 response rate in moderate to severe psoriasis at 12 weeks.
News
Elevated type 2 diabetes risk seen in PsA patients
Type 2 diabetes risk was significantly higher among patients with psoriatic arthritis, even when compared with patients with psoriasis alone.
News
Psoriatic arthritis activity spikes briefly postpartum
News
Infliximab biosimilar only moderately less expensive in Medicare Part D
Without biosimilar gap discounts in 2017, beneficiaries would have paid nearly $1,700 more in projected out-of-pocket costs for infliximab-dyyb...
News
Sustained minimal disease activity in PsA reduced CV risk factors
Achieving sustained minimal disease activity in psoriatic arthritis is associated with significant improvements in atherosclerotic disease risk...
News
Risankizumab proves more effective in psoriasis than ustekinumab
Two phase 3 trials suggested that risankizumab can do more to improve quality of life, with similar safety.
News
Psoriasis registry study provides more data on infliximab’s infection risk
Infliximab was associated with a statistically significant increased risk of serious infection, compared with non-biologic systemic treatments.